Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Bonus News The Often-Missed Corner of Healthcare That Wall Street Is LovingReported by Nathan Reiff. Published: 3/29/2026. 
Key Points - Numerous lab equipment stocks are down in the high-teens so far this year, but seemingly modest sales growth may hide fundamental strengths.
- These companies can present a more secure approach to the healthcare industry than some higher-risk alternatives.
- Still, headwinds including tariff impacts and inflation remain a concern.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
The healthcare industry is notoriously volatile—company fortunes can be made or broken on the success of a single product or the results of a clinical trial—and it's not uncommon for stocks in this sector to register some of the market's biggest spikes and drops. Investors who want exposure to the healthcare space but are wary of that turbulence may prefer a "picks and shovels" approach: focusing on companies that provide essential equipment and services to the industry rather than higher-risk pharmaceutical names. Lab equipment stocks are often overlooked, even though some companies in this subindustry rank among the largest in healthcare. With a range of external factors that could affect healthcare in 2026—shifting subsidies, an aging population, inflation, and the growing role of AI, among others—core lab-equipment names may be especially attractive. Below are several major players worth a closer look for investors considering this part of the market. A Recent Dip Masks Thermo Fisher's Long-Term Strengths Elon Musk Just Called the Dollar "Hopeless" – Then Reinvented It What's going on with Elon Musk? Last year, he launched a full-blown attack on the U.S. dollar, calling it "hopeless." And within months, he hatched a plan to reinvent the world reserve currency. Now, with the blessing of President Trump and the U.S. Treasury, it's coming to life. And investors who grasp what's going on could make a fortune. Full story here. $182 billion life sciences solutions, diagnostics, and analytical instruments company Thermo Fisher Scientific (NYSE: TMO) has had a difficult start to 2026, with shares down more than 15% year-to-date and the company recently entering TradeSmith's red zone for financial health. A sizable portion of the weakness appears tied to tariffs and FX volatility, which together pressured margins by over 100 basis points in 2025. That said, there are several bright spots in Thermo Fisher's recent performance. In Q4 2025, revenue of $12.2 billion rose 7% year-over-year, beating analyst estimates by roughly $250 million. Adjusted earnings per share also topped expectations at $6.57. Momentum may be supported by recent product launches, including the Orbitrap Astral Zoom mass spectrometer and new bioreactor offerings. Thermo Fisher's diversified business model and broad product portfolio should help cushion it against external headwinds. Even if 2026 guidance is conservative—revenue is projected to grow 4% to 6%—expected EBITDA-margin improvements and steady customer demand are positives. That likely explains why, despite the selloff, analysts remain bullish: 17 of 19 rate the stock a Buy or equivalent, and consensus estimates imply more than 29% upside. Danaher's Business May Be Improving, Even as Guidance Remains Modest Danaher Corp. (NYSE: DHR) shares are down nearly 20% YTD as the instruments, consumables, and reagents firm navigates a similar environment to Thermo Fisher. While 2026 guidance calls for modest core revenue growth of 3% to 6% year-over-year, the latest quarter included top- and bottom-line beats and the company generated $5.3 billion in free cash flow for 2025. Two potential drivers for 2026 are Danaher's bioprocessing business, which should deliver high-single-digit revenue growth driven by strong monoclonal antibody demand, and diagnostics. Diagnostics stand to benefit from recent FDA clearances, and equipment orders appear to be improving after a prolonged slowdown—both trends that could help sales recover. Analysts are reasonably optimistic on DHR, forecasting about 12.3% earnings growth over the next year and roughly 35% upside in the share price. That optimism is reflected in ratings: 19 of 22 analysts rate the stock a Buy. Agilent's Biocare Purchase Could Be a Catalyst Agilent Technologies (NYSE: A) lagged the peers above in its most recent earnings, reporting only 4.4% year-over-year revenue growth and narrowly missing analyst expectations on both revenue and earnings. However, Agilent's acquisition of Biocare Medical could provide a meaningful growth catalyst by expanding its presence in cancer diagnostics. At nearly $1 billion, the Biocare purchase was sizable, but it should add recurring revenue in a high-demand area. Cancer diagnostics may also carry higher margins than some of Agilent's legacy lines, which could help lift operating margins (Agilent's stood at 24.6% in the last quarter). Despite a roughly 17% YTD decline, analysts see substantial upside for Agilent, with consensus estimates suggesting about 42% potential appreciation. Wall Street classifies the stock as a Moderate Buy, with 13 of 16 ratings at Buy or similar. | 
